Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 8/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23825285 | 1.00 | RIPK1 (0.38) | RIPK1KDM1AKDM1BSCN9ADPP4 | |
| SCHEMBL29200705 | 1.00 | RIPK1 (0.38) | RIPK1KDM1AKDM1BSCN9ADPP4 | |
| SCHEMBL22013223 | 0.87 | TRPA1 (0.44) | RIPK1KDM1AKDM1BSCN9ADPP4 | |
| SCHEMBL17848946 | 0.79 | KDM1A (0.41) | RIPK1KDM1AKDM1BSCN9AJAK2 | |
| SCHEMBL28623843 | 0.77 | DPP4 (0.38) | RIPK1KDM1AKDM1BDPP4JAK2 | |
| SCHEMBL28623840 | 0.77 | DPP4 (0.38) | RIPK1KDM1AKDM1BDPP4JAK2 | |
| SCHEMBL28613334 | 0.76 | TRPA1 (0.45) | RIPK1KDM1AKDM1BDPP4JAK2 | |
| SCHEMBL28613335 | 0.76 | TRPA1 (0.45) | RIPK1KDM1AKDM1BDPP4JAK2 | |
| SCHEMBL25587655 | 0.75 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL17821020 | 0.74 | CYP1A2 (0.44) | SCN9AJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| EP-3919490-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD (CN) | 2025-04-02 | — | — | EP | disclosed |
| CN-113166142-B | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114641476-B | Preparation and application of protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-113166141-B | Hexa-membered and hexa-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114641476-A | Preparation and application of protein receptor kinase inhibitor | 上海轶诺药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3919490-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3919490-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021098745-A1 | PREPARATION AND APPLICATION OF A CLASS OF PROTEIN RECEPTOR KINASE INHIBITORS | 上海轶诺药业有限公司 | 2021-05-27 | — | — | WO | disclosed |
| CN-111362946-A | Pharmaceutical compound and composition and application thereof | 上海度德医药科技有限公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2020114465-A1 | PREPARATION AND APPLICATION OF HETEROAROMATIC IMINAZOLE COMPOUND | 上海轶诺药业有限公司 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020098723-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
| WO-2020098720-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | RIPK1 115/4885KDM1A 4285/4885KDM1B 4029/4885 |
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | GRK6, GRK3, ERBB2 | RIPK1 110/4885KDM1A 4101/4885KDM1B 3997/4885 |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, GRK3, ERBB2 | RIPK1 110/4885KDM1A 4101/4885KDM1B 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.